Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026)

Edgewise Therapeutics has disclosed Retained Earnings across 7 years of filings, most recently posting -$252000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$252000.0, down 162.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$252000.0 (down 162.84% YoY), and the FY2025 annual result was -$546.4 million, down 130188.33% from the prior year.
• Retained Earnings came in at -$252000.0 for Q1 2026 at Edgewise Therapeutics, up from -$546.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $420000.0 in Q4 2024 to a low of -$546.4 million in Q4 2025.
• The 5-year median for Retained Earnings is -$144.6 million (2022), against an average of -$172.9 million.
• Across the five-year window, Retained Earnings slumped 326263.64% in 2022 and soared 119.35% in 2025, its largest moves.
• Edgewise Therapeutics' Retained Earnings stood at -$144.6 million in 2022, then tumbled by 69.27% to -$244.8 million in 2023, then surged by 100.17% to $420000.0 in 2024, then sank by 130188.33% to -$546.4 million in 2025, then jumped by 99.95% to -$252000.0 in 2026.
• The last three Retained Earnings figures came in at -$252000.0 (Q1 2026), -$546.4 million (Q4 2025), and -$496.2 million (Q3 2025), per Business Quant data.